Onkologie. 2023:17(5):335-341 | DOI: 10.36290/xon.2023.063

Trends in the treatment of metastatic castration-sensitive prostate cancer

Markéta Dvořáková, Tomáš Büchler
Onkologická klinika, 2. LF UK a Fakultní nemocnice v Motole, Praha

There has been significant progress in recent years in the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). While for patients with less extensive or less aggressive disease, a combination of androgen deprivation (ADT) and hormonal agents aimed at inhibiting androgen receptor signaling (ARTA) is recommended, for patients in good overall condition with high-volume disease and especially synchronous metastases, the new standard of treatment is intensified initial therapy using a triplet of ADT+ARTA+docetaxel.

Keywords: metastatic hormone sensitive prostate cancer, ARTA, intensified triplet therapy, docetaxel, enzalutamide.

Accepted: November 28, 2023; Published: November 29, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dvořáková M, Büchler T. Trends in the treatment of metastatic castration-sensitive prostate cancer. Onkologie. 2023;17(5):335-341. doi: 10.36290/xon.2023.063.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Preisser F, Chun KH, Banek S, et al. Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer. Prostate International [Internet]. 2021;9(3):113-118 [cit. 2023-09-02]. Available from: doi:10.1016/j.prnil.2020.12.003. Go to original source... Go to PubMed...
    2. Sutera P, Eecken van Der K, Kishan AU, et al. Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. Prostate Cancer and Prostatic Diseases [Internet]. 2022;25(4):713-719 [cit. 2023-09-02]. Available from: doi:10.1038/s41391-021-00484-4. Go to original source... Go to PubMed...
    3. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians [Internet]. 2021;71(3):209-249 [cit. 2023-09-02]. Available from: doi:10.3322/caac.21660. Go to original source... Go to PubMed...
    4. Siegel DA, O'Neil ME, Richards TB, et al. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity - United States, 2001-2017. MMWR. Morbidity and Mortality Weekly Report [Internet]. 2020;10-16;69(41):1473-1480 [cit. 2023-09-03]. Available from: doi:10.15585/mmwr.mm6941a1. Go to original source... Go to PubMed...
    5. Vale CL, Fisher DJ, Godolphin PJ, et al. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. The Lancet Oncology [Internet]. 2023;24(7):783-797 [cit. 2023-09-02]. Available from: doi:10.1016/S1470-2045(23)00230-9. Go to original source... Go to PubMed...
    6. Francini E, Gray GP, Xie W, et al. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). The Prostate [Internet]. 2018;78(12):889-895 [cit. 2023-09-02]. Available from: doi:10.1002/pros.23645. Go to original source... Go to PubMed...
    7. Kyriakopoulos ChE, Chen YH, Carducci MA, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. Journal of Clinical Oncology [Internet]. 2018;04-10,36(11): 1080-1087 [cit. 2023-09-02]. Available from: doi:10.1200/JCO.2017.75.3657. Go to original source... Go to PubMed...
    8. Fizazi K, Tran NP, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. New England Journal of Medicine [Internet]. 20171;-07-27, 377(4): 352-360 [cit. 2023-09-02]. Available from: doi:10.1056/NEJMoa1704174. Go to original source... Go to PubMed...
    9. James ND, Bono de JS, Spears MR, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. New England Journal of Medicine [Internet]. 2017;07-27, 377(4):338-351. [cit. 2023-09-02]. Available from: doi:10.1056/NEJMoa1702900. Go to original source... Go to PubMed...
    10. Modrá kniha České onkologické společnosti [Internet]. 29. Brno: Masarykův onkologický ústav; 2023 [cit. 2023-09-02]. Available from: https://www.linkos.cz/lekar-a-multidisciplinarni-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/.
    11. Astellas Pharma EuropeE B.V. Xtandi product information. 21. 6 2013. Availeble from: https://www.ema.europa.eu/en/documents/product-information/xtandi-epar-product-information_cs.pdf.
    12. Wenzel M, Nocera L, CollÀ Ruvolo C, et al. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Prostate Cancer and Prostatic Diseases [Internet]. 2022;25(2):139-148 [cit. 2023-09-05]. Available from: doi:10.1038/s41391-021-00395-4. Go to original source... Go to PubMed...
    13. Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. New England Journal of Medicine [Internet]. 2019;07-04:381(1):13-24 [cit. 2023-09-02]. Available from: doi:10.1056/NEJMoa1903307. Go to original source... Go to PubMed...
    14. Bayer AG. Nubeqa product information. 27. 3. 2020. Available from: https://www.bayer.com/sites/default/files/Nubeqa%20-%20SPC%20-%2027.2.2023.pdf.
    15. Sweeney Ch, Chen YH, Carducci MA, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. Journal of Clinical Oncology [Internet]. 2014;06-20:32(18_suppl):LBA2-LBA2 [cit. 2023-09-02]. Available from: doi:10.1200/jco.2014.32.18_suppl.lba2. Go to original source...
    16. Parker CE, Castro K, Fizazi A, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology [Internet]. 2020;31(9):1119-1134 [cit. 2023-09-02]. Availeble from: doi:10.1016/j.annonc.2020.06.011. Go to original source... Go to PubMed...
    17. Feyerabend S, Saad F, Li T, et al. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis. European Journal of Cancer [Internet]. 2018;103:78-87 [cit. 2023-09-02]. Available from doi:10.1016/j.ejca.2018.08.010. Go to original source... Go to PubMed...
    18. Parker ChC, James ND, Brawley ChD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. The Lancet [Internet]. 2018;392(10162):2353-2366 [cit. 2023-09-02]. Available from: doi:10.1016/S0140-6736(18)32486-3. Go to original source... Go to PubMed...
    19. Mittal A, Sridhar SS, Ong M, et al. Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC) - A Potential New Standard of Care. Current Oncology [Internet]. 2023; 30(4):4365-4378 [cit. 2023-09-02]. Available from: doi:10.3390/curroncol30040332. Go to original source... Go to PubMed...
    20. Davis ID, Martin EJ, Stockler MR, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. New England Journal of Medicine [Internet]. 2019;07-11:381(2):121-131 [cit. 2023-09-02]. Available from: doi:10.1056/NEJMoa1903835. Go to original source... Go to PubMed...
    21. Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. The Lancet [Internet]. 2022;399(10336):1695-1707 [cit. 2023-09-02]. Available from: doi:10.1016/S0140-6736(22)00367-1. Go to original source... Go to PubMed...
    22. Smith MR, Hussain M, Saad F, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. New England Journal of Medicine [Internet]. 2022;03-24:386(12):1132-1142 [cit. 2023-09-02]. Available from: doi:10.1056/NEJMoa2119115. Go to original source... Go to PubMed...
    23. Sweeney ChJ, Martin AJ, Stockler MR, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. The Lancet Oncology [Internet]. 2023;24(4):323-334 [cit. 2023-09-02]. Available from: doi:10.1016/S1470-2045(23)00063-3. Go to original source... Go to PubMed...
    24. Abdel-Aty H, James ND. The role of radiotherapy in oligometastatic hormone-sensitive prostate cancer. Current Opinion in Urology [Internet]. 2022;32(3):277-282 [cit. 2023-09-02]. Available from: doi:10.1097/MOU.0000000000000980. Go to original source... Go to PubMed...
    25. Deek MP, Eecken van Der K, Sutera P, et al. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. Journal of Clinical Oncology [Internet]. 2022;10-10:40(29):3377-3382 [cit. 2023-09-02]. Available from: doi:10.1200/JCO.22.00644. Go to original source... Go to PubMed...
    26. Phillips R, Shi WY, Deek M, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer. JAMA Oncology [Internet]. 2020;05-01:6(5) [cit. 2023-09-02]. Available from: doi:10.1001/jamaoncol.2020.0147. Go to original source... Go to PubMed...
    27. Dai B, Zhang J, Wang H, et al. 618MO Local therapy to the primary tumour for newly diagnosed, oligo-metastatic prostate cancer: A prospective randomized, phase II, open-label trial. Annals of Oncology [Internet]. 2020;31 [cit. 2023-09-02]. Available from: doi:10.1016/j.annonc.2020.08.877. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.